Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonuclease H2 subunit B is an essential non-catalytic subunit of the RNase H2 enzyme complex, which, together with subunits A and C, is responsible for removing misincorporated ribonucleotides from DNA and degrading RNA/DNA hybrids formed during replication and transcription. Its key structural feature is a C-terminal PIP box motif, allowing interaction with proliferating cell nuclear antigen (PCNA) and localization to DNA replication foci, thus facilitating genome surveillance and repair. Mutations in RNASEH2B disrupt ribonucleotide excision repair and cause Aicardi-Goutières syndrome, a severe neuroinflammatory and autoimmune disease characterized by immune system activation due to accumulated DNA damage and faulty nucleic acid metabolism. This subunit does not possess enzymatic activity by itself but is critical for the function and stability of the RNase H2 complex.
For a hypothetical inhibitor: prevention of ribonucleotide excision repair, increased genome instability, or modulation of immune response For genetic rescue/modification: restoration of ribonucleotide excision function, reduction of R-loop accumulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonuclease H2 subunit B (RNASEH2B).